甲磺酸伊马替尼(格列卫)治疗晚期慢性粒细胞性白血病的临床疗效观察  

Clinical observation on the effect of imatinibme sylate(Gleevec) for the treatment of advanced chronic myelogenous leukemia

作　　者：吴健晖[1] 林丽娥[2] 

机构地区：[1]海南省人民医院药学部,海南海口570311 [2]海南省人民医院血液科,海南海口570311

出　　处：《中国医院药学杂志》2012年第7期522-524,共3页Chinese Journal of Hospital Pharmacy

基　　金：海南省自然科学基金资助项目(编号:30843)

摘　　要：目的:探讨甲磺酸伊马替尼(格列卫)治疗晚期慢性粒细胞白血病的临床疗效及不良反应情况。方法:对我院近年来应用甲磺酸伊马替尼治疗的29例晚期慢性粒细胞白血病患者的临床资料进行回顾性分析,并记录治疗过程中各时间点血常规、骨髓细胞形态学检查、细胞遗传学检查情况,对临床疗效及不良反应进行评价。结果:急变期CML患者血液学缓解率为28.6%,完全细胞遗传学缓解率为0,均明显低于加速期CML患者的73.3%和26.7%,差异均有统计学意义。治疗过程中血液学不良反应主要以白细胞,血小板减少多主,非血液学不良反应可有恶心、呕吐、水肿、骨骼肌酸痛、乏力、头昏、头痛、皮疹等。结论:甲磺酸伊马替尼治疗慢性粒细胞白血病加速期急变期患者疗效好,不良反应少,可耐受且加速期疗效优于急变期。OB.IECTINE To explore the clinical curative effect and adverse reactions of Gleevec （imatinibme sylate）for the treatment advanced chronic myelogenous leukemia. METHODS Clinical data of 29 patients with advanced chronic myelogenous leukemia treating with Gleevec were retrospectively analyzed, and record the healing process each time point of routine blood, bone marrow cell morphology inspection,cytogenetics examination,and assess the clinical curative effect and adverse reactions. RESULTS The hematology remission rate of acute changed period CML patients was 28. 6%complete cytogenetic remission rate was 0, and were significantly lower than accelerating period CML patients（73.3 % and 26.7 %）. In the treatment process, hematology adverse reactions were leckocytes and platelets reduced, the no hematology adverse reactions were nausea, vomi- ting, edema, skeletal muscle pain, weakness, dizziness, headache, skin rash,etc. CONCLUSION Gleevec treatment for chron ic myeloid leukemia accelerating period had a good curative effect, fewer side effects, and the curative effect for accelerating period patients was better that for the acute changed period.

关 键 词：甲磺酸伊马替尼 慢性粒细胞白血病 加速期 急变期 

分 类 号：R453[医药卫生—治疗学]